US/UK/Canada

Share

Pick a time period -
Tags ( Active)

Mayo Clinic presents first clinical case with EndoDrill[®] GI in the lower GI tract at ESGE Days 2026

BiBBInstruments AB (“BiBB” or the “Company”) announces that physicians at world-renowned Mayo Clinic in Jacksonville, Florida, presented clinical experience with EndoDrill[®] GI at ESGE Days 2026. The presented case demonstrated successful endoscopic ultrasound-guided core biopsy using EndoDrill[®] GI of a lesion adjacent to the rectum. The biopsy resulted in ample tissue acquisition in a single pass and without reported adverse events. “We are encouraged to see Mayo Clinic present additional clinical experience with EndoDrill[®] GI, this time in the lower GI tract. The findings confirm

Notice of annual general meeting in BiBBInstruments AB

The shareholders of BibbInstruments AB, reg. no. 556938-9512 (the "Company"), are hereby invited to attend the annual general meeting on Friday, 12 June 2026, at 3:00 p.m. at Medicon Village, Scheeletorget 1, SE-223 63 Lund, room "Utsikten", floor 4 in building 405.Right to participate and notification Shareholders wishing to attend the general meeting shall: · be entered in the share register kept by Euroclear Sweden AB on Thursday, 4 June 2026, and · notify the Company no later than Monday, 8 June 2026, by e-mail to info@bibbinstruments.com. Notification may also be made by

Henry Ford Health Presented Case Series with Positive Clinical Results for EndoDrill GI at DDW 2026 in Chicago

BiBBInstruments AB (“BiBB” or the “Company”) announces that a clinical case series demonstrating positive results for EndoDrill[®] GI was presented at Digestive Disease Week (DDW) 2026 in Chicago, the world’s leading congress in gastroenterology and advanced endoscopy, attracting over 13,000 attendees from around the globe. In the presented case series from Henry Ford Health in Detroit, the authors concluded that “EndoDrill[®] device demonstrated strong diagnostic utility in an effective and safe manner.” The BiBB team attended the congress together with the Company’s U.S. distribution

BiBBInstruments carries out a directed issue of shares to guarantors

THIS PRESS RELEASE MAY NOT BE DISTRIBUTED, RELEASED OR PUBLISHED, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR ANY OTHER JURISDICTION WHERE SUCH DISTRIBUTION, DISCLOSURE OR PUBLICATION WOULD BE IN VIOLATION OF APPLICABLE LAWS OR REQUIRE ADDITIONAL REGISTRATION OR OTHER ACTIONS. PLEASE REFER TO THE SECTION “IMPORTANT INFORMATION” AT THE END OF THIS PRESS RELEASE. The Board of Directors of BiBBInstruments AB (“BiBBInstruments” or the “Company”) has today, based on

Shareholding notification in BiBBInstruments AB (publ)

BiBBInstruments AB (publ) (“BiBBInstruments” or the “Company”) hereby announces, in connection with the recently completed rights issue in the Company, that the shareholding of Life Science Invest Fund 1 ApS (LSIF) in the Company will exceed the notification thresholds of 5 and 10 percent of the total number of shares and votes in the Company, and that the shareholding of CHWA AB in the Company will fall below the notification threshold of 5 percent of the total number of shares and votes in the Company, once the shares from the rights issue have been registered with the Swedish Companies

BiBBInstruments announces outcome in rights issue

The Board of Directors of BiBBInstruments AB (“BiBBInstruments” or the “Company”) today announces the outcome of the rights issue of shares that was announced on 19 March 2026 (the “Rights Issue”). The outcome shows that 79,132,017 shares, corresponding to approximately 48.6 percent of the Rights Issue, have been subscribed for by exercise of subscription rights. In addition, 12,922,811 shares have been subscribed for without exercise of subscription rights, corresponding to approximately 7.9 percent of the Rights Issue. The Rights Issue is thereby subscribed to approximately 56.5 percent and

BiBBInstruments receives additional subscription intentions in the ongoing rights issue

THIS PRESS RELEASE MAY NOT BE DISTRIBUTED, RELEASED OR PUBLISHED, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR ANY OTHER JURISDICTION WHERE SUCH DISTRIBUTION, DISCLOSURE OR PUBLICATION WOULD BE IN VIOLATION OF APPLICABLE LAWS OR REQUIRE ADDITIONAL REGISTRATION OR OTHER ACTIONS. PLEASE REFER TO THE SECTION “IMPORTANT INFORMATION” AT THE END OF THIS PRESS RELEASE. BiBBInstruments AB (“BiBBInstruments” or the “Company”) is conducting a rights issue of approximately

Correction: BiBBInstruments AB (publ) publishes updated information document in connection with rights issue – incorrect ISIN code for the share

BiBBInstruments AB (publ) (“BIBB” or the “Company”) today publishes an updated information document in connection with the rights issue of shares resolved by the Company’s Board of Directors on 18 March 2026 (the “Rights Issue”). The correction relates to an incorrect ISIN code for the Company’s share in the information document published on 24 March 2026. The correct ISIN code for the Company’s share is SE0010102095. The information document is otherwise unchanged.NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, HONG

BiBBInstruments AB (publ) publishes information document in connection with rights issue

BiBBInstruments AB (publ) (“BIBB” or the “Company”) today publishes an information document in connection with the rights issue of shares resolved by the Company’s Board of Directors on 18 March 2026, based on the authorization from the extraordinary general meeting held on 13 March 2026 (the “Rights Issue”). If the Rights Issue is fully subscribed, the Company will receive approximately SEK 60 million before transaction costs. The Rights Issue is covered by subscription commitments and guarantee undertakings totaling approximately SEK 41.9 million, corresponding to approximately 69.5 per

BiBBInstruments resolves on the previously announced rights issue of approximately SEK 60.3 million

THIS PRESS RELEASE MAY NOT BE DISTRIBUTED, RELEASED OR PUBLISHED, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR ANY OTHER JURISDICTION WHERE SUCH DISTRIBUTION, DISCLOSURE OR PUBLICATION WOULD BE IN VIOLATION OF APPLICABLE LAWS OR REQUIRE ADDITIONAL REGISTRATION OR OTHER ACTIONS. PLEASE REFER TO THE SECTION ”IMPORTANT INFORMATION” AT THE END OF THIS PRESS RELEASE. The Board of Directors of BiBBInstruments AB (“BiBBInstruments” or “the Company”) announced through a

Communiqué from the Extraordinary General Meeting in BiBBInstruments AB held on 13 March 2026

Today, March 13, 2026, an extraordinary general meeting was held in BiBBInstruments AB (publ) (“BiBB” or “the Company”). Below is a summary of the resolutions adopted. The resolutions were adopted by the required majority.Resolution to amend the Articles of Association The meeting resolved, in accordance with the Board’s proposal, to amend the provisions of the Articles of Association regarding limits on share capital and the number of shares. The Board of Directors has prepared three alternative proposals for amendments to the Articles of Association—Alternative A, Alternative B, and

Notice of Extraordinary General Meeting of BiBBInstruments AB (publ)

The shareholders of BibbInstruments AB (publ), 556938-9512, are hereby invited to attend an extraordinary general meeting on Friday, March 13 2026, at 3:00 p.m. at Medicon Village, Scheeletorget 1, 223 81 Lund, Sweden, in the "Utsikten" room, floor 4, building 405.Right to participate and registration Shareholders who wish to participate in the general meeting must · be listed in the share register maintained by Euroclear Sweden AB on March 5, 2026, and · register with the company no later than on March 9, 2026 by email to info@bibbinstruments.com. Registration can also be made

BiBBInstruments Announces the Board of Directors’ Intention to Resolve on a Rights Issue of Approximately SEK 60 Million

THIS PRESS RELEASE MAY NOT BE DISTRIBUTED, RELEASED OR PUBLISHED, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR ANY OTHER JURISDICTION WHERE SUCH DISTRIBUTION, DISCLOSURE OR PUBLICATION WOULD BE IN VIOLATION OF APPLICABLE LAWS OR REQUIRE ADDITIONAL REGISTRATION OR OTHER ACTIONS. PLEASE REFER TO THE SECTION ”IMPORTANT INFORMATION” AT THE END OF THIS PRESS RELEASE. The Board of Directors of BibbInstruments AB (“BiBBInstruments” or “the Company”) today announces its

BiBBInstruments receives additional orders for EndoDrill[®] GI from the U.S.

The cancer diagnostics company BiBBInstruments AB (“BiBB” or the “Company”) announces that additional orders have so far been received from the Company’s U.S. distribution partner, TaeWoong Medical USA, with a total value of $31,840 (SEK 300,000) during the fourth quarter. The orders form part of the targeted launch in the U.S. that was initiated in the fall. TaeWoong is focused on establishing regular use at a number of larger reference hospitals, which will serve as the foundation for a broader nationwide launch in 2026. In parallel, discussions are ongoing with potential distribution

U.S. Tour Fall 2025 – BiBB Strengthens Its Presence in the American Market

BiBBInstruments AB (“BiBB” or the “Company”), a cancer diagnostics company, has recently completed a successful tour across the United States – an important step in the initial commercialization of EndoDrill[®] GI in the world’s largest market for ultrasound-guided endoscopic tissue sampling (EUS/EBUS). During the trip, BiBB met with representatives from six leading hospitals and supported TaeWoong Medical USA (“TaeWoong”) in education and clinical introductions of EndoDrill[®] GI. The Company also received further confirmation of the clear clinical need for high-quality core biopsies, while

EndoDrill GI has officially launched in the United States.

BiBBInstruments AB (“BiBB” or the “Company”), a Swedish cancer diagnostics company, announces the official launch of EndoDrill[®] GI in the United States together with its partner TaeWoong Medical USA (“TaeWoong”). EndoDrill[®] GI is the world’s first market-cleared, powered biopsy instrument for endoscopic ultrasound (EUS). The launch has started with the first customer orders, and TaeWoong has submitted an initial commercial order to BiBB valued at approximately USD 11,700. During November and December 2025, several U.S. hospitals will evaluate EndoDrill[®] GI in clinical use, with BiBB’s

Initial Results from Mayo Clinic Indicate Potential of EndoDrill GI in Tissue Culture-Based Pancreatic Cancer Research

BiBBInstruments AB (“BiBB” or the “Company”), a cancer diagnostics company, today announces that a research team from Mayo Clinic in Jacksonville (Florida) has presented a poster at the Department of Medicine Research & Innovation Day of a research project using BiBB’s EndoDrill[®] GI to sample core biopsies for tissue slice cultures. The initial results included three patients with solid pancreatic tumors (PDAC). Tissue samples were acquired using standard manually operated fine needles (EUS-FNA and EUS-FNB) as well as motorized biopsy sampling with EndoDrill[®] GI. The research team

BiBB Engages EUS Pioneer Professor Peter Vilmann as Scientific Advisor

BiBBInstruments AB (“BiBB” or the “Company”), a cancer diagnostics company, today announces that Professor Peter Vilmann, a world-renowned pioneer who performed the first endoscopic ultrasound-guided fine needle aspiration (EUS-FNA) in 1991, will serve as Scientific Advisor. He brings extensive expertise in endoscopic ultrasound-guided biopsy and therapy and will provide scientific support to the Company while contributing to its clinical roadmap.“We are very pleased to have the opportunity to benefit from the expertise of a true pioneer in the field of EUS biopsy. Professor Vilmann is an

Henry Ford St. John Hospital Reports First U.S. Liver Biopsy Cases with EndoDrill GI

The cancer diagnostics company BiBBInstruments AB ("BiBB" or the "Company") today announces that Henry Ford St. John Hospital & Medical Center in Detroit has reported the first U.S. case series with EndoDrill[®] GI that includes endoscopic ultrasound-guided (EUS) liver biopsies. The evaluation, led by Dr. Mohammed Barawi and conducted with his team at Henry Ford St. John Hospital, was presented at a regional medical conference and demonstrated the device’s ability to obtain diagnostic tissue from both the liver and pancreas.The series comprises four patients, three with suspected liver

Decision to Grant Third EndoDrill[®] Patent in Japan

Cancer diagnostics company BiBBInstruments AB ("BiBB" or the "Company"), developer of EndoDrill[®] – the world’s first market-cleared powered biopsy instrument for endoscopy – today announces that the Company has received a Decision to Grant from the Japan Patent Office (JPO). This means that the JPO has decided to approve BiBB’s third patent application in Japan for EndoDrill[®]. A few formal steps remain before the patent is finally granted, after which it will be valid until 2041. Once the process is finalized, this will become the third granted patent in Japan for the EndoDrill[®]

BiBBInstruments announces date for conversion of exercised warrants of series TO 1 into shares

BiBBInstruments AB (“BiBB” or the “Company”) announces that the Swedish Companies Registration Office has registered the shares subscribed for through the exercise of warrants of series TO 1 (“TO 1”). A total of 514,916 TO 1 were exercised for the subscription of 514,916 shares in the Company. This increases the number of shares in the Company to 40,739,302 and the share capital in the Company increases by SEK 43,767.86 to SEK 3,462,840.67. The record date is June 26, 2025, after which it is expected that the shares will be admitted to trading on Spotlight Stock Market and distributed to

BiBB signs exclusive distribution agreement with TaeWoong Medical USA

BiBBInstruments AB ("BiBB" or the "Company"), developer of EndoDrill[®] – the world's first market-cleared powered biopsy instrument for endoscopy – announces today that the Company has signed an exclusive distribution agreement with TaeWoong Medical USA ("TaeWoong") for the sales, marketing, and commercialization of its flagship product EndoDrill[® ]GI in the U.S. market. The agreement follows a previously announced Letter of Intent on May 2, 2025. The collaboration began during DDW in San Diego, May 4–6 – the world’s largest GI congress – where EndoDrill[® ]GI was showcased and received

BiBBInstruments AB announces outcome of subscription period for warrants of series TO 1

BiBBInstruments AB (”BiBB” or the ”Company”) today announces the outcome of the subscription period för warrants of series TO 1 (the ”Warrants” or ”TO 1”), which were issued in connection with the Company’s rights issue of units, the subscription period for which ended during the first quarter of 2025 (the “Rights Issue”). During the subscription period, which was held from May 22, 2025, to June 5, 2025, a total of 514,916 Warrants were exercised, corresponding to approximately 18.7 percent of all outstanding Warrants, for the subscription of 514,916 new shares in BiBB. The subscription price

There are no items matching the current filter
There are no more items matching the current filter
Back to top

Subscribe